Brief: Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations

Xencor

04/10/2021 12:48

Oct 4 (Reuters) - Xencor Inc  XNCR.O :
    * XENCOR ENTERS GLOBAL COLLABORATION AND LICENSE AGREEMENT
WITH
JANSSEN TO ADVANCE PLAMOTAMAB AND XMAB CD28 BISPECIFIC ANTIBODY
COMBINATIONS FOR THE TREATMENT OF PATIENTS WITH B-CELL
MALIGNANCIES
    * XENCOR INC - SECOND AGREEMENT WITH JANSSEN ON BISPECIFIC
ANTIBODIES DIRECTED TOWARD CD28 CO-STIMULATORY RECEPTOR ON T
CELLS
    * XENCOR INC - XENCOR TO RECEIVE $100 MILLION UPFRONT
PAYMENT AND
$25 MILLION EQUITY INVESTMENT
    * XENCOR INC - ELIGIBLE FOR A MID-TEEN TO LOW-TWENTIES
PERCENT
ROYALTY FOR PLAMOTAMAB AND POTENTIAL MILESTONE PAYMENTS UP TO
$1.188 BILLION
    * XENCOR INC - JANSSEN WILL RECEIVE WORLDWIDE EXCLUSIVE
DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO PLAMOTAMAB
    * XENCOR INC - XENCOR WILL COLLABORATE WITH JANSSEN ON
FURTHER
CLINICAL DEVELOPMENT OF PLAMOTAMAB
    * XENCOR - JANSSEN PAYING 80% AND XENCOR PAYING 20% OF
COSTS,
INCLUDING THOSE FOR SUBCUTANEOUS FORMULATION ANTICIPATED TO
ENTER CLINICAL TRIALS IN 2022

Source text for Eikon:  ID:nBw6rTjL7a 
Further company coverage:  XNCR.O